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Activation of Toll-like receptor 5 in microglia 
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Abstract 
Microglia are the primary immune-competent cells of the central nervous system (CNS) and sense both pathogen- 
and host-derived factors through several receptor systems including the Toll-like receptor (TLR) family. Although TLR5 
has previously been implicated in different CNS disorders including neurodegenerative diseases, its mode of action 
in the brain remained largely unexplored. We sought to determine the expression and functional consequences of 
TLR5 activation in the CNS. Quantitative real-time PCR and immunocytochemical analysis revealed that microglia is 
the major CNS cell type that constitutively expresses TLR5. Using Tlr5−/− mice and inhibitory TLR5 antibody we found 
that activation of TLR5 in microglial cells by its agonist flagellin, a principal protein component of bacterial flagella, 
triggers their release of distinct inflammatory molecules, regulates chemotaxis, and increases their phagocytic activity. 
Furthermore, while TLR5 activation does not affect tumor growth in an ex vivo GL261 glioma mouse model, it triggers 
microglial accumulation and neuronal apoptosis in the cerebral cortex in vivo. TLR5-mediated microglial function 
involves the PI3K/Akt/mammalian target of rapamycin complex 1 (mTORC1) pathway, as specific inhibitors of this 
signaling pathway abolish microglial activation. Taken together, our findings establish TLR5 as a modulator of micro-
glial function and indicate its contribution to inflammatory and injurious processes in the CNS.
Keywords: Toll-like receptor 5, Microglia, PI3K/Akt/mTORC1 signaling, Cytokines, Phagocytosis, Chemotaxis, Neuronal 
apoptosis
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Background
Toll-like receptors (TLRs) are pattern recognition recep-
tors that are activated by both pathogen- and host-
derived, potentially damage-associated, molecular 
patterns [61]. Engagement of these membrane recep-
tors in the brain can result in various outcomes, such as 
chronic inflammation, neuronal injury, either in a cell-
autonomous or inflammation-associated fashion, or in 
regenerative processes [36, 40, 57]. Among the 13 mem-
bers of the TLR family in mouse and human character-
ized to date, TLR5 is the only protein-binding TLR that 
is conserved in vertebrates from fish to mammals, and 
specifically recognizes flagellin, a fibrillar protein derived 
from bacteria [22, 31, 59]. Examples of flagellated bac-
teria are Escherichia coli and Salmonella Typhi, which 
both can enter the central nervous system (CNS), thereby 
causing meningitis and/or brain abscesses [1, 9, 19, 34]. 
Furthermore, recent studies identified TLR5 as being 
involved in different CNS disorders lacking a primarily 
Open Access
*Correspondence:  seija.lehnardt@charite.de
†Masataka Ifuku, Lukas Hinkelmann, Helmut Kettenmann, Seija Lehnardt 
contributed equally.
2 Institute of Cell Biology and Neurobiology, Charité – Universitätsmedizin 
Berlin, corporate member of Freie Universität Berlin, Humboldt-
Universität zuBerlin, and Berlin Institute of Health, Berlin, Germany
Full list of author information is available at the end of the article
Page 2 of 19Ifuku et al. acta neuropathol commun           (2020) 8:159 
pathogen-associated cause, including Alzheimer’s disease 
(AD), neuropathic pain, and cerebral ischemia [7, 24, 33, 
64]. In peripheral immune cells such as dendritic cells 
and monocytes, and epithelial cells, flagellin-induced 
activation of TLR5 triggers PI3K signaling resulting in 
NF-κB activation, thereby modulating the innate immune 
response [13, 15, 47, 48, 56]. However, the TLR5-induced 
signaling cascade in the CNS is unresolved.
Microglia are the brain’s primary sensor for pathologic 
events and express all TLRs identified so far, including 
TLR5 [52]. Activation of distinct TLRs can affect diverse 
microglial functions including migration (via TLR7, [29]) 
and cytokine release (via TLR2, TLR4, TLR7, [5, 38, 40]). 
In the present study, we sought to systematically ana-
lyze the expression and function of TLR5 in the CNS. 
In particular, we focused on the molecular mechanisms 
and signaling pathway promoting microglial chemotaxis, 
phagocytosis, cytokine production, and interaction with 
glioma cells as a consequence of TLR5 activation in these 
cells. Furthermore, we analyzed whether microglial TLR5 
activation may lead to neuronal injury.
Methods
Reagents
Purified recombinant flagellin from Salmonella Typh-
imurium (FLA-ST Ultrapure) and loxoribine were 
purchased from InvivoGen (San Diego, CA, USA). 
Lipopolysaccharide (LPS) was purchased from Enzo Life 
Sciences (Lörrach, Germany). LY294002 was obtained 
from Cell Signaling Technology (Danvers, MA, USA), 
while wortmannin and rapamycin were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Akt inhibi-
tor IV was obtained from Calbiochem (San Diego, CA, 
USA). LY294002, Wortmannin, and rapamycin were 
solved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. 
Louis, MO, USA). In all experiments using the inhibi-
tors, DMSO-containing DMEM medium complete (see 
below; DMSO dilution at 1:1000 vol/vol) served as nega-
tive control. Anti-mTLR5 neutralizing IgG antibody was 
obtained from InvivoGen.
Mice and cell lines
C57BL/6 (wild-type, WT) mice were obtained from the 
Charité animal facility, Berlin, Germany, or purchased 
from Charles River Laboratory (Wilmington, MA, USA). 
Tlr5−/− (B6.129S1-Tlr5tm1Flv/J (Tlr5, stock no. 008377)) 
mice were bred at the animal facility of the Department 
of Veterinary Medicine, Robert-von-Ostertag Haus, Freie 
Universität Berlin, Germany, from a line originally devel-
oped in the S. Akira laboratory [62]. Tlr2/4−/− mice were 
bred at the Charité animal facility, Berlin, Germany. Ani-
mals were maintained and handled in accordance with 
the German Animal Protection Law and approved by the 
Regional Office for Health and Social Services in Berlin 
(Landesamt für Gesundheit und Soziales – LAGeSo, Ber-
lin, Germany).
Oli-neu cells were generously provided by Dr. J. Trot-
ter (Institute of Molecular Biology, Johannes Gutenberg-
University, Mainz, Germany [11]) and were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin (DMEM complete; all obtained from 
Invitrogen, Darmstadt, Germany).
Mouse glioma (GL) 261 cells (Charles River Labora-
tory, Wilmington, MA, USA) were lentivirally transduced 
for fluorescence labeling. Briefly, mCherry gene was 
cloned into a lentiviral vector on a pRRL backbone (https 
://www.addge ne.org/12252 /), downstream of the MP71 
promoter. After production of viral particles, GL261 cells 
were transduced at an MOI (multiplicity of infection) of 
1 for 24 h using Roswell Park Memorial Institute (RPMI) 
medium supplemented with 10% fetal calf serum (FCS), 
2% glutamine, 1% penicillin/streptomycin, and 0.4  mg/
ml polybrene (all obtained from Merck, Darmstadt, 
Germany). Transduction was stopped by adding fresh 
medium. MCherry-labeled GL261 cells were selected via 
FACS cell sorting and frozen until further use.
Primary cell cultures of microglia, astrocytes, and neurons
Neonatal primary microglia cultures were prepared 
from cerebral cortex and midbrain of newborn male 
and female P0-P3 C57BL/6, Tlr5−/−, or Tlr2/4−/− mice, 
as described previously [40, 55]. In brief, forebrain was 
freed of blood vessels and meninges. Cortical tissue was 
dissociated by a fire-polished pipette using 3 ml of 2.5% 
trypsin for 2  min and washed twice with phosphate-
buffered saline (PBS). Mixed glial cells were cultured for 
9-12 d in DMEM (Invitrogen, Darmstadt, Germany) sup-
plemented with 10% FCS and 1% penicillin/streptomy-
cin (Gibco, New York, USA), with medium change every 
third day. Microglial cells were separated from the under-
lying glial layer by gentle shaking of the flasks for 1  h 
at 37  °C in 5%  CO2 humidified atmosphere on a shaker 
(100  rpm) and plated (for densities, see specific experi-
mental approaches below). Resulting cell cultures usually 
contained > 95% microglia, as detected by isolectin b4 
(IB4) staining (for details see below). Cells were main-
tained at 37 °C in 5%  CO2 humidified atmosphere.
Microglia from adult mice were prepared as described 
previously [54]. In short, brains derived from P49-P56 
male mice were freed of blood vessels and meninges, 
mechanically dissociated, and digested with 2.5% trypsin 
and 1  mg/ml DNase (Roche Diagnostics, Mannheim, 
Germany). After further dissociation, cells were plated 
on a confluent monolayer of P0-P2 astrocytes in 75-cm2-
flasks. The feeding astrocytic layer was depleted of 
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neonatal microglia using clodronate (200  µg/ml) before 
plating the microglial cells (for densities, see specific 
experimental set-ups below). Mixed adult and neonatal 
glial cultures were maintained in fresh DMEM, supple-
mented as described above, and medium was changed 
every third day, followed by addition of 33% L292-condi-
tioned medium at day 7. After a further week, cells were 
shaken off and used for experiments within 24-48 h.
Cultures of cortical neurons were generated from fore-
brains of E17 mice, as described previously [40]. In brief, 
brains were separated from blood vessels, meninges, and 
cerebellum. Cortical tissue was treated with 500  µl of 
2.5% trypsin (Gibco, New York, USA) for 20 min at 37 °C. 
Trypsin activity was stopped by 4  ml FBS (Invitrogen, 
Darmstadt, Germany). Thereafter, cells were washed with 
PBS and incubated with 100 µl DNase (1 mg/ml; Roche 
Diagnostics, Mannheim, Germany) for 1  min. Subse-
quently, cells were washed, centrifuged, and seeded on 
poly-d-lysine-coated (Sigma-Aldrich, St. Louis, USA) 
glass coverslips with a diameter of 12  mm, at a density 
of 500,000 cells/well of a 24-well-plate, unless stated oth-
erwise, with Neurobasal Medium (Gibco) supplemented 
with 1% L-Glutamin, 1% penicillin/streptomycin, and 
2% B27 supplement (all obtained from Gibco, New York, 
USA). Cells were maintained at 37 °C in 5%  CO2 humidi-
fied atmosphere. On the following day, half of media was 
replaced, and cells were incubated for additional 48  h 
before starting experiments.
Primary astrocytes were isolated, as previously 
described [39]. In detail, mixed glial cultures were pre-
pared from mouse brains, as described above (see neona-
tal primary microglia). After separation of microglial cells 
from the underlying glial layer by gentle shaking of the 
flasks for 1 h at 37  °C on a shaker (100 rpm), cells were 
trypsinized (2.5%), and subsequently plated at a density 
of 80,000 cells/well of a 24-well-plate for immunocyto-
chemical analysis.
For microglia/neuron co-culture experiments half of 
the medium of 500,000 cultured neurons was replaced by 
DMEM containing 62,500 microglia (ratio 8:1) at day 3 
after plating. On the following day, cultures were used for 
experiments.
Multiplex immune assay
Detection of TNF-α, IL-6, IL-10, IL-1β, GRO-α (CXCL1), 
macrophage inflammatory protein 2 (MIP-2 or CXCL2) 
and RANTES (CCL5) in 50  μl supernatant collected 
from microglial cell cultures (density of 30,000/200  μl 
medium/well of a 96-well-plate) stimulated over time 
with flagellin was performed using the ProcartPlex 
mouse Multiplex Immunoassay Mix & Match (Affyme-
trix eBioscience, Vienna, Austria) according to the manu-
facturer’s manual. Briefly, the magnetic bead-based assay 
enables the simultaneous detection and quantification 
of multiple proteins in a single sample. Prior to incuba-
tion, samples were vortexed followed by centrifugation to 
remove particles. Proteins were detected using Luminex 
200. Analysis was performed using Bioplex System Soft-
ware 4.0 (Bio-Rad, Hercules, CA, USA).
Nitric oxide release assay
The amount of nitric oxide (NO) was determined using 
the colorimetric Griess reaction (Sigma-Aldrich, St. 
Louis, MO, USA), as previously described [41]. In detail, 
primary neonatal cultured microglia were seeded in 
a 96-well-plate at a density of 30,000/well. Cells were 
incubated in DMEM complete (see above) for 24  h in 
a total volume of 200  µl/well. Flagellin was added at a 
concentration of 100 ng/ml. 100 ng/ml LPS was used as 
positive control. After 24  h, 100  µl of supernatant were 
transferred to a fresh 96-well-plate. Solution A (100 mg 
naphthylethylene in 50 ml aqua dest.) and solution B (1 g 
sulfanilamide and 6 ml 85%  H3PO4 in 44 ml aqua dest.) 
were mixed at the ratio of 1:1 shortly before use. Subse-
quently, the mixed solution was added to the wells con-
taining the microglial supernatant at 1:1 ratio. A nitrite 
standard curve was prepared. Absorbance was measured 
at 550 nm.
Agarose spot assay
Agarose spot assay for chemotactic invasion was per-
formed, as previously described [63]. In summary, 0.1 g 
of low-melting point agarose (Promega, Madison, WI, 
USA) was diluted in 20 ml of PBS originating a 0.5% aga-
rose solution. Subsequently, the solution was heated until 
boiling and then cooled down to 40 °C. Afterwards, 90 µl 
of agarose solution were mixed with 10  µl of PBS with 
or without flagellin at indicated doses in a 0.5 ml Eppen-
dorf tube. Ten µl of the mixed solution were plated onto 
35- mm-glass-bottomed dishes (Mattek Corporation, 
Ahland, MA, USA) and were cooled down for 10 min at 
4 °C. Four spots were pipetted in one dish, of which two 
contained PBS only and two contained PBS with flagel-
lin. 500,000 microglial cells were plated onto the dish in 
2 ml DMEM complete (see above) and incubated at 37 °C 
in 5%  CO2 humidified atmosphere for 3 h. Subsequently, 
cells inside the spot were quantified by microscopy. To 
assess microglial motility versus chemotaxis, flagellin 
was additionally applied to the medium. For chemotaxis 
assays, flagellin was only present within the spot. Val-
ues are expressed as the average obtained from 6 dishes. 
When inhibitors (LY294002, 25 or 50 μM; Wortmannin, 
0.1 or 1 μM; rapamycin, 100 μM; Akt inhibitor IV; 1 or 10 
μM) were added, cells were pre-treated for 30 min before 
plated onto the dish.
Page 4 of 19Ifuku et al. acta neuropathol commun           (2020) 8:159 
Boyden chamber assay
Flagellin-induced chemotaxis was tested using a 48-well-
microchemotaxis Boyden chamber (Neuroprobe, 
Bethesda, MD, USA). Upper and lower wells were sepa-
rated by a polycarbonate filter (8 μm pore size; Poret-
ics, Livermore, CA, USA). 20,000-40,000 microglial 
cells in 50 μl of serum-free DMEM were added to the 
upper compartment, while lower wells contained flagel-
lin in serum-free DMEM. Serum-free DMEM alone was 
used as control. For signaling inhibition experiments, 
cells were pre-treated with PI3K inhibitors (LY294002; 
25 or 50 μM; Wortmannin; 0.1 or 1 μM), mTOR inhibi-
tor (rapamycin; 10 or 100 μM), and with anti-mTLR5 
antibody (1 μg/ml) for 30  min on ice before added to 
the upper compartment. The chamber was incubated at 
37 °C and 5%  CO2 for 6 h. Cells remaining on the upper 
surface of the membrane were removed by wiping, while 
cells in the lower compartment were fixed in methanol 
for 10  min and subjected to Diff-Quik stain (Medion 
Grifols Diagnostics AG, Duedingen, Switzerland). Rate 
of microglial migration was calculated counting cells 
in 4 random fields of each well using a 20 × bright-field 
objective. For each condition, 2-4 fields in 4-8 wells were 
analyzed. Under control conditions, ~ 40-80 cells were 
present per field, and numbers of cells in each field were 
normalized to the average derived from control condition 
(set to 100%).
Flow cytometry‑based phagocytosis assay
After isolation of microglia as described above, cells 
were resuspended in DMEM (Thermo Fisher Scientific, 
Waltham, MA, USA) supplemented with 10% FCS and 
2  ml  l-glutamine at 37  °C. Microglial cells were seeded 
onto primary cultured neonatal astrocytes overnight, 
as described previously [46]. Fluoresbrite Carboxy-
late Micropheres (BrightBlue, 4.5 μm) were coated with 
5% FCS for 30 min at room temperature on a shaker at 
1000  rpm. Beads were resuspended in Hank’s balanced 
salt solution at a final concentration of 2 x  106 beads per 
ml. Microglia-astrocyte co-cultures were washed once 
with Hank’s balanced salt solution before 1  ml bead 
solution was applied. Cells were incubated with beads 
for 30  min at 37  °C in 5%  CO2 humidified atmosphere. 
Afterwards, they were washed in fluorescence-activated 
cell sorting buffer. Cells were stained with CD11b anti-
body (1:50; eBioscience, San Diego, CA, USA) for 15 min 
at 4 °C. After staining, cells were washed in fluorescence-
activated cell sorting buffer and pulled down at 500 g for 
5 min. Cells were resuspended in propidium iodide solu-
tion (ratio of 1:1000 in fluorescence-activated cell sorting 
buffer) to stain dead cells. Stained cells were transferred 
to a BD LSRFortessa Flow cytometer (BD Bioscience, 
Heidelberg, Germany). The phagocytic index implements 
the total number of cells that phagocytosed, and the 
number of beads taken up by a given cell. Data were ana-
lyzed using FlowJo v10 software (Tree Star, Ashland, OR, 
USA).
Toxicity assay in vitro
For toxicity studies, indicated amounts of flagellin and 
other reagents were added to neuron/microglia co-cul-
tures (ratio 8:1; 500,000 neurons and 62,500 microglial 
cells per well of a 24-well-plate) or isolated neurons 
(500,000 neurons per well of a 24-well-plate) for various 
time periods, as indicated. Control cultures remained 
unstimulated. LPS (100 ng/ml) served as positive control 
for microglia-mediated neurodegeneration in co-cul-
tures. Loxoribine (1  mM) served as positive control for 
TLR7-mediated apoptosis of neurons. For each condi-
tion, experiments were performed in duplicates. NeuN- 
and TUNEL-positive cells (in situ Cell Death Detection 
Kit, TMR red or Fluorescein, Roche Diagnostics, Man-
nheim, Germany) were counted analyzing 5 fields per 
coverslip. Control condition was set to 100%. Numbers of 
NeuN- and TUNEL-positive cells observed for each con-
dition were compared with control.
Intrathecal injection
Intrathecal injection of 6-8-week-old male C57BL/6 
mice with 1 μg flagellin in a volume of 40 μl PBS was per-
formed as described previously [25, 36]. PBS alone served 
as control. After transcardial perfusion with 4% para-
formaldehyde, brains were removed and cryoprotected 
in 30% sucrose. Neuronal survival and microglial num-
bers were analyzed by blinded quantification of cortical 
NeuN-/active caspase-3-positive cells and Iba1-positive 
cells, respectively, in 6 fields (magnification x60) of 5 rep-
resentative sections of each brain (see below).
Glioma ex vivo model
Organotypic brain slice preparation was performed as 
previously described [45]. Brains from P14-P16 C57BL/6 
and Tlr5−/− mice were placed in ice-cold PBS. Cerebel-
lum and olfactory bulb were removed and the forebrain 
cut in the coronal plane into 250-μm-sections using 
a vibratome (Microm HM650V, Thermo Scientific, 
Waltham, MA, USA). Brain slices were transferred onto 
0.4  μm-polycarbonate membranes of a transwell insert 
(Falcon model 3090, Becton–Dickinson, Franklin Lakes, 
NJ, USA), which was inserted into a 6-well-plate (Fal-
con model 3502, Becton–Dickinson, Franklin Lakes, 
NJ, USA). Brain slices were incubated in 1 ml of culture 
medium per well containing DMEM supplemented with 
10% heat-inactivated FBS (Gibco, Thermo Fisher Scien-
tific, Waltham, MA, USA), 0.2  mM glutamine, and 1% 
penicillin/streptomycin). After overnight equilibration, 
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slices were incubated with medium containing 25% 
FBS (Atlanta Biological, Norcross, GA, USA), 50  mM 
sodium bicarbonate, 2% glutamine, 25% Hank’s balanced 
salt solution, 1  μg/ml insulin, 5  mM Tris (all from Life 
Technologies, Carlsbad, CA, USA), 2.46  mg/ml glucose 
(Braun, Melsungen, Germany), 0.8 mg/ml vitamin C, 100 
U/ml penicillin, and 100  μg/ml streptomycin (all from 
Sigma-Aldrich, St. Louis, MO, USA) in DMEM (Gibco, 
Thermo Fisher Scientific, Waltham, MA, USA). Slices 
were cultured for 5 d with medium change every 2 d. For 
flagellin stimulation experiments, flagellin (100  ng/ml) 
was added to the medium on day 1 and 3 after slicing.
The day after sectioning, 5000 cultured mCherry 
GL261 glioma cells in a volume of 0.1  μl were injected 
into the slices using a microsyringe mounted to a micro-
manipulator. An injection canal was formed that reached 
150 μm deep into the 250-μm-thick slice. The needle was 
then retracted by 50  μm, thereby forming an injection 
cavity of about 50 μm depth. The tumor cell suspension 
was slowly inoculated into the cavity, and the syringe was 
pulled out. To ensure identical experimental conditions, 
gliomas were always inoculated in the striatal area of 
both hemispheres.
On day 4 after injection organotypic brain slices were 
fixed with 4% PFA for 1 h, washed with PBS and stained 
with Hoechst (1:4750) before being washed again and 
mounted. Tumor volumes were determined by confo-
cal microscopy (Leica TCS SPE, Leica Microsystems, 
Wetzlar, Germany). Images were acquired with a 20x oil 
immersion objective using a z-stack with a 2-μm-step-
size interval and tile scan mode. Tumor volume was 
assessed using Imaris 9.2 (Bitplane, Zürich, Switzerland). 
Tumor volumes were 3D-rendered by application of 1 μm 
object detail, 15-threshold background, and 1000 tridi-
mensional pixels (voxels). The surface objects obtained 
were unified in one single object, and values for volume 
mean were extracted.
Immunocytochemistry, immunohistochemistry, and TUNEL 
assay
Immunostaining was performed as described previously 
[41]. In detail, representative brain sections (level 1: 
interaural 6.60  mm; level 2: 5.34  mm; level 3: 3.94  mm; 
level 4: 1.86  mm; level 5: −0.08  mm) or cell cultures 
(microglia at a density of 80,000/well, astrocytes at a den-
sity of 80,000/well, neurons at a density of 300,000/well; 
all cell types were seeded on 12-mm-glass cover slips in a 
24-well-plate) were fixed with 4% PFA (200 μl), washed 3x 
with 200 μl PBS, and treated with blocking solution (5% 
normal goat serum (NGS) for brain sections or 2% NGS 
for cell cultures; 0.2% TritonX-100) for 1  h. The follow-
ing primary antibodies were used: TLR5 (clone 19D759.2, 
ab13876, Abcam, Cambridge, UK, 1:200), NeuN (ABN 
78, Sigma-Aldrich, St. Louis, MO, USA, 1:500), active 
caspase-3 (#9661, Asp175, Cell Signaling Technology, 
1:500), S100β (ab227914; Abcam, Cambridge, UK, 1:250) 
and Iba1 (#019-19741, Wako, 1:500). Isolectin b 4 (IB4) 
was obtained from Invitrogen (Carlsbad, CA, USA). 
Cells and brain sections were incubated with the respec-
tive antibody overnight at 4  °C. Subsequently, they were 
washed 3x with PBS incubated with the relevant sec-
ondary antibody (# A-11001, Alexa Fluor 488 goat anti-
mouse IgG; # A-11004, Alexa Fluor 568 goat anti-mouse 
IgG; #  A-11008, Alexa Fluor 488 goat anti-rabbit IgG; 
# A-11011, Alexa Fluor 568 goat anti-rabbit IgG; all used 
in 1:500 dilution and purchased from Invitrogen, Eugene, 
OR, USA) for 1  h at room temperature. Finally, nuclei 
were stained with 4′,6-diamidino-2-phenylindole (DAPI) 
solution (1:10,000, D9542, Sigma-Aldrich, St. Louis, MO, 
USA) for 1 min and washed 3x in PBS. Coverslips were 
attached onto glass slides using 1 drop of ImmuMount 
(#9990402; Thermo Scientific, Waltham, MA, USA)/
coverslip.
Numbers of neurons and microglia in the cerebral cor-
tex within brain sections were assessed by blinded quan-
tification of NeuN- and Iba1-positive cells in 3 fields per 
hemisphere (x60 magnification) at level 4 of the 5 repre-
sentative sections of each brain (see above). For analysis 
of apoptosis, brain sections were stained by active cas-
pase-3 and DAPI and quantified as described for NeuN- 
and Iba1-stained cells above. The mean was calculated, 
which is expressed as NeuN-positive, Iba1-positive, or 
active caspase-3-positive cells per  mm2. Each group is 
displayed with the median. An Olympus BX51 micro-
scope and a Leica TCS SL confocal laser-scanning micro-
scope were used.
Western blot
Western blot analysis was performed using whole lysates 
of  106 cultured microglia per dish. Before collection, cells 
were washed with cold PBS. Radioimmunoprecipita-
tion assay (RIPA) buffer was used as lysis buffer contain-
ing 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS 
dissolved in 1% TBS buffer. Protease inhibitor cocktail 
(Roche, Grenzach-Wyhlen, Germany) and phosphatase 
inhibitor mixture (Sigma-Aldrich, Darmstadt, Germany) 
were added to RIPA buffer before cell lysis. Cells were 
homogenized by a syringe needle, followed by centrifu-
gation at 15,000 rpm for 10 min to remove insoluble cell 
debris. Protein concentration was measured by BCA 
protein assay kit (Thermo Fisher Scientific, Waltham, 
MA, USA), and a total of 20  μg protein was separated 
by 10% SDS-PAGE and subsequently electrophoreti-
cally transferred onto polyvinylidene difluoride (PVDF) 
membranes (Bio-Rad Laboratories, Hercules, CA, USA). 
After protein transfer, PVDF membranes were blocked 
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with Tris-buffered saline containing 5% bovine serum 
albumin (BSA) for 1 h at room temperature. Membranes 
were then incubated at 4  °C overnight with antibodies 
against phospho-AKT (S-473) and Akt purchased from 
Cell Signaling Technology (Danvers, MA, USA). Mem-
branes were washed and incubated with anti-rabbit IgG 
secondary antibody (Cell Signaling Technology, Danvers, 
MA, USA) at room temperature for 2  h. Protein signal 
transferred onto the PVDF membrane was visualized 
by ECL Prime Western Blotting Detection Reagent (GE 
Healthcare, Buckinghamshire, UK) using the Chemi Doc 
XRS system (Bio-Rad Laboratories, Hercules, CA, USA). 
Quantification of signals was assessed using Image J 
software.
Quantitative real‑time PCR
Primary neonatal microglia, adult microglia, astrocytes, 
neurons, or Oli-neu cells were seeded at a density of  106 
cells per dish in a 6-well-plate. After 24 h, cells were stim-
ulated with flagellin (100 ng/ml) for 24 h. Subsequently, 
cell lysates were collected and RNA was extracted, fol-
lowed by cDNA synthesis and quantitative PCR expres-
sion analysis. Primers directed against TLR5 and TNF-α 
were purchased from QIAGEN (Hilden, Germany). For 
details of the qPCR cycle program used please refer to 
the Thermo Scientific Maxima SYBR Green/ROX qPCR 
Master Mix manual.
Statistics
Data are expressed as mean ± SEM or ± SD. Statistical 
differences between selected groups were determined 
using Dunnett’s or Tukey’s multiple comparison test 
after one-way ANOVA, Kruskal–Wallis test followed by 
Dunn’s multiple comparison post hoc test, or Student’s t 
test, as indicated. Statistical differences were considered 
significant when P < 0.05.
Results
In the CNS, TLR5 is primarily expressed in microglia, 
and its activation triggers PDK1 and Akt phosphorylation 
in a PI3K‑dependent fashion
TLR5 was previously reported being expressed in micro-
glia and dorsal root ganglion neurons [52, 64]. We com-
pared expression levels of TLR5 in murine CNS glial 
cells and neurons by quantitative RT-PCR. Among the 
different CNS cell types (for images of cultured primary 
microglia, neurons, and astrocytes, please refer to Addi-
tional file  1), microglia expressed the highest levels of 
TLR5, of which adult microglia expressed higher TLR5 
expression levels than neonatal microglia. Compared 
to microglia, astrocytes and Oli-neu cells, a mouse oli-
godendroglial precursor line, expressed low levels of 
TLR5, while this receptor was barely detectable in pri-
mary cortical neurons (Fig. 1a). TLR5 protein was read-
ily detectable in cultured neonatal microglia, but also in 
astrocytes, although to a much lesser extent, by immuno-
cytochemistry. In contrast, TLR5 protein expression was 
not detected in cortical neurons (Fig.  1b). Specificity of 
the antibody to TLR5 was confirmed by analyzing micro-
glia from Tlr5−/− mice (Fig. 1b).
Flagellin-induced TLR5 activation was previously 
shown to induce PI3K, as evidenced by Akt phospho-
rylation, a downstream effector of PI3K and 3-phospho-
inositide-dependent kinase-1 (PDK1), thereby mediating 
regulation of proinflammatory gene expression in epi-
thelial cells [51, 67]. To investigate this signaling pathway 
in microglia, we exposed neonatal microglia to flagel-
lin and subsequently assessed their p-Akt expression by 
western blot. In response to flagellin, p-Akt expression 
was significantly increased after 30  min and decreased 
to control level at 60  min (Fig.  1c). Flagellin-induced 
Akt phosphorylation was abolished by the PI3K inhibi-
tors LY294002 and Wortmannin (Fig. 1d). Furthermore, 
(See figure on next page.)
Fig. 1 TLR5 is constitutively expressed in microglia, and its activation triggers PDK1 and Akt phosphorylation in a PI3K-dependent manner. a 
Relative TLR5 expression levels were assessed in primary neonatal microglia, primary adult microglia, primary astrocytes, and primary cortical 
neurons isolated from C57BL/6 mice, as well as Oli-neu cells by quantitative RT-PCR (fold-change compared to neurons). TATA sequence binding 
protein (TBP) was used as housekeeping control (n = 3). Results are represented as mean ± SD. Data were analyzed by one-way ANOVA followed by 
Newman-Keuls test. *P < 0.05; **P < 0.01. b Cultured neonatal microglia, astrocytes, and neurons from C57BL/6 (WT) mice, as well as microglia from 
Tlr5−/− mice were stained with antibody directed against TLR5 and co-stained with Iba1, S100β, or NeuN antibody serving as microglial, astrocyte, 
and neuronal marker, respectively. Scale bar, 10 μm. c Western blot analysis of microglial lysates using antibodies against p-Akt and total Akt after 
incubation of microglia with 100 ng/ml flagellin (FLA) for 0, 5, 15, 30, or 60 min (n = 3). Representative blots are shown in the upper panel. The 
graph depicts the average intensity ratio of the bands compared to control (lower panel). Data are expressed as mean ± SEM and were analyzed 
by one-way ANOVA followed by Dunnett’s post hoc test. **P < 0.01 vs. control. d Western blot analysis of FLA-mediated Akt phosphorylation after 
treatment of microglia with LY294002 (25 and 50 μM), Wortmannin (0.1 and 1 μM), and anti-mTLR5-IgG (1 μg/ml) (upper panel, n = 3). The graph 
shows the average intensity ratio of the bands compared to control (lower panel). e Western blot analysis of microglial lysates with antibodies 
against p-PDK1 and β-actin after incubation of microglia with 100 ng/ml FLA, FLA plus LY294002 (25 and 50 μM), FLA plus Wortmannin (0.1 and 
1 μM), and FLA plus anti-mTLR5-IgG (1 μg/ml) (upper panel, n = 3). The graph depicts average intensity ratio of the bands compared to control 
(lower panel). Data are expressed as mean ± SEM and were analyzed by one-way ANOVA followed by Tukey’s post hoc test. **P < 0.01 vs. control; 
##P < 0.01 vs. FLA. d, e DMSO-containing DMEM served as control, while FLA was solved in DMSO-containing DMEM
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flagellin-induced Akt phosphorylation was depend-
ent on functional TLR5, as TLR5-neutralizing antibody 
significantly diminished this response (Fig.  1d). Next, 
flagellin-treated microglia were analyzed for phosphoryl-
ated PDK1 (p-PDK1) expression. Western blot analysis 
revealed an increase in p-PDK1 expression in response 
to flagellin after 30  min, and LY294002 and wortman-
nin significantly inhibited these effects (Fig. 1e). Employ-
ment of the TLR5-neutralizing antibody reduced levels of 
p-PDK1, thereby confirming TLR5 as the signaling recep-
tor in flagellin-induced PDK1 phosphorylation (Fig. 1e).
Activation of TLR5 and subsequent PI3K/Akt/mTORC1 
signaling in microglia results in the release of distinct 
inflammatory molecules
Activation of various TLRs results in the release 
of inflammatory molecules including cytokines, 
chemokines, and nitric oxide (NO) from microglia [37]. 
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However, the role of TLR5 in microglia in this context 
has not been explored. Thus, to determine the specific 
inflammatory response pattern induced by activation of 
microglial TLR5, we analyzed supernatants from neona-
tal wild-type (WT) and Tlr5−/− microglia incubated with 
100  ng/ml flagellin after 24  h by multiplex immunoas-
say. Specific cytokines and chemokines were selected for 
analysis based on their relevance in the context of neu-
roinflammation and neurodegenerative diseases, as well 
as on their suitability as microglial activation markers 
[23, 50, 58]. LPS as the established TLR4 ligand served 
as positive control. TNF-α, RANTES, MIP-2, IL-10, 
IL-6, and GRO-α were significantly released from WT 
microglia in response to flagellin, while IL-1β was not 
detected (Fig. 2a; for protein concentrations of detected 
cytokines/chemokines please refer to Additional file  2). 
Notably, LPS induced an enhanced MIP-2 response in 
Tlr5−/− microglia compared to WT cells (Fig. 2a). Induc-
tion of all tested cytokines in flagellin-treated microglia 
required TLR5, as Tlr5−/− microglia failed to respond 
to flagellin (Fig.  2a). To assess dose-dependent effects, 
microglia were incubated with increasing doses of flagel-
lin up to 1000  ng/ml, and their supernatants were sub-
sequently analyzed for selected cytokines by multiplex 
immunoassay. We observed a dose-dependent increase 
in TNF-α, RANTES, MIP-2, and GRO-α in response to 
10  ng/ml and 100  ng/ml flagellin compared to control 
condition. However, microglia exposed to 1000  ng/ml 
flagellin released diminished amounts of these cytokines 
compared to microglia responding to 100 ng/ml flagellin 
(Fig. 2b). This cytokine reduction observed at 1000 ng/ml 
flagellin was not due to potential flagellin-induced toxic-
ity towards microglia, as quantification of IB4-positive 
cells and TUNEL staining of flagellin-treated cells did 
not indicate cellular injury or loss, even when microglia 
were exposed to doses up to 5  μg/ml flagellin (Addi-
tional file 3). Induction of cytokines, as indicated above, 
in Tlr2/4−/− microglia was similar to that of WT cells 
after exposure to flagellin, excluding the possibility of rel-
evant contamination of recombinant flagellin with LPS 
or TLR2 ligands (data not shown) and confirming the 
results derived from Tlr5−/− microglia with respect to 
receptor specificity. Further, in contrast to LPS, flagellin 
did not induce NO production in microglia, as assessed 
by Griess assay (Fig. 2c).
To determine whether flagellin-induced release of 
cytokines from microglia requires PI3K/Akt signaling, 
microglia were incubated with flagellin in the presence or 
absence of LY294002 or Wortmannin for 6 h, and mRNA 
expression levels of TNF-α-a representative cytokine 
produced in activated microglia, were determined by 
quantitative RT-PCR. As expected, PI3K inhibitor treat-
ment inhibited TNF-α mRNA expression in microglia 
exposed to flagellin (Fig.  2d). Likewise, presence of the 
mammalian target of rapamycin complex 1 (mTORC1) 
inhibitor rapamycin in microglial cultures prevented 
TNF-α expression in these cells (Fig. 2d). Pre-treatment 
with the TLR5-neutralizing antibody also diminished 
flagellin-induced TNF-α mRNA expression in microglia, 
thereby confirming TLR5 as the responsible immune 
receptor in this context (Fig. 2d).
Taken together, flagellin induced the release of distinct 
cytokines from microglia depending on TLR5 and PI3K/
Akt/mTORC1 signaling.
Flagellin modulates microglial chemotaxis through TLR5 
and PI3K/Akt/mTORC1 signaling
To test the effect of flagellin on microglial migration, we 
analyzed cell accumulation in an agarose spot containing 
either flagellin or PBS serving as control (Fig. 3a). Micro-
glia that had migrated into the agarose spot after 6  h, 
were quantified. At a dose of 10  ng/ml flagellin, micro-
glia did not significantly migrate, whereas the migration 
rate was significantly increased in response to 50 ng/ml 
and 100 ng/ml flagellin (Fig. 3b). To determine whether 
flagellin induces cell motility or directed migration, i.e. 
chemotaxis, 100 ng/ml flagellin was added either to the 
spot only, or to both spot and surrounding superna-
tant. Presence of flagellin increased microglial motility 
only in the presence of a gradient, as this effect was not 
observed when the gradient was absent (Fig. 3c). To con-
firm flagellin-induced chemotaxis, we tested microglia 
in a further migration assay, the Boyden chamber. Here, 
we observed similar effects as observed with the agarose 
spot assay. However, in the Boyden chamber, flagellin 
increased microglial migration at flagellin doses as low 
as 10 ng/ml (Fig. 3d). When flagellin was added to both 
top and bottom wells, thereby disseminating the gradi-
ent, no significant increase in microglial migration was 
detected (Fig. 3e). TLR5 served as the responsible recep-
tor in flagellin-induced microglial chemotaxis, as pre-
treatment with the TLR5-neutralizing antibody inhibited 
migration in a dose-dependent fashion (Fig. 3f ).
We reported previously that TLR2 and TLR7 agonist-
induced microglial migration is inhibited by treatment 
with the PI3K inhibitors LY294002 and wortmannin, sug-
gesting that signaling through PI3K contributes to TLR-
induced microglial migration [29]. To analyze the PI3K/
Akt signaling pathway in flagellin-induced microglial 
chemotaxis, we again made use of the migration assays 
described above testing a dose of 100  ng/ml flagellin. 
In both agarose spot assay (Fig.  3g) and Boyden cham-
ber (Fig.  3h) pre-treatment with LY294002 (at 25 and 
50  μM) and Wortmannin (at 0.1 and 1  μM) for 30  min 
inhibited flagellin-induced microglial migration. To fur-
ther characterize the signaling cascade through which 
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Fig. 2 Flagellin induces the release of cytokines and chemokines from microglia through TLR5 signaling. a Multiplex immunoassay was used 
to detect cytokines/chemokines, as indicated, in supernatants of cultured neonatal microglia from C57BL/6 (WT) and Tlr5−/− mice in response 
to 100 ng/ml flagellin (FLA) after 24 h. Unstimulated cells served as negative control, while LPS (100 ng/ml) was used as positive control (n = 3). 
b Supernatants of cultured neonatal WT microglia stimulated with 10 ng/ml, 100 ng/ml, 1000 ng/ml FLA, or 100 ng/ml LPS were analyzed for 
indicated cytokines/chemokines after 24 h by multiplex immunoassay. Unstimulated cells served as control (n = 3). Results are expressed as 
mean ± SEM. Data were analyzed by Kruskal–Wallis test followed by Dunn’s post hoc test. *P < 0.05; **P < 0.01 vs. control. c Cultured neonatal WT 
microglia were stimulated with 100 ng/ml FLA and/or 100 ng/ml LPS for 24 h, and supernatants were analyzed for NO using Griess assay (n = 3). 
Results are expressed as mean ± SEM. Data were analyzed by Kruskal–Wallis test followed by Dunn’s post hoc test. **P < 0.01 vs. control; n.s., not 
significant. d WT microglia were incubated with 100 ng/ml FLA alone or in combination with LY294002 (50 μM), Wortmannin (1 μM), rapamycin 
(100 μM), or anti-mTLR5-IgG (1 μg/ml) for 6 h. DMSO-containing DMEM served as control, while FLA was solved in DMSO-containing DMEM. 
Subsequently, quantitative RT-PCR using primers against TNF-α was performed. TBP served as housekeeping gene (n = 5). Results are expressed as 
normalized to control and are represented as mean ± SD. Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. **P < 0.01 vs. 
control; ##P < 0.01 vs. FLA
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PI3K regulates flagellin-induced migration, we included 
the established mTORC1 inhibitor rapamycin (at 10 and 
100  μM) and Akt inhibitor IV (1  μM) in the migration 
analysis. Pretreatment with both inhibitors for 30  min 
inhibited flagellin-induced microglial motility, suggest-
ing that this process is dependent on Akt and mTORC1 
signaling (Fig.  3h, i). TLR5 as the responsible receptor 
in flagellin-induced microglial migration (see Fig.  3f ) 
was confirmed using the Boyden chamber assay as pre-
treatment with the TLR5-neutralizing antibody inhibited 
migration (Fig. 3h).
In summary, these results indicate that flagellin is a 
chemotactic signal for microglia mediated by TLR5 and 
PI3K/Akt/mTORC1 signaling.
Microglial phagocytosis is enhanced in response 
to flagellin and dependent on TLR5 and PI3K/Akt/mTORC1 
signaling
To examine whether flagellin affects the phagocytic activ-
ity of microglia, we analyzed the uptake of fluorescent 
beads through flow cytometry. Fluorescent beads were 
added to microglia for 30  min, and subsequently, cells 
were isolated and stained with CD11b antibody. Expo-
sure to flagellin for 30 min significantly increased phago-
cytic activity of microglia. The number of cells containing 
one, two, and more beads were significantly increased in 
flagellin-exposed cell cultures, while the number of cells 
lacking beads decreased (Fig. 4a, b). This effect was com-
pletely abolished in the presence of LY294002, Wortman-
nin, and rapamycin, indicating that PI3K/Akt/mTORC1 
signaling was required in flagellin-induced microglial 
phagocytosis. Furthermore, increased phagocytic activ-
ity of microglia in response to flagellin was dependent 
on TLR5, as TLR5-neutralizing antibody abolished this 
effect (Fig. 4b).
In contrast to TLR 2/4/7, TLR5 does not mediate 
microglia‑glioma interaction
TLRs play an important role for the interaction of micro-
glia with glioma cells promoting a pro-tumorigenic phe-
notype including TLR2, TLR4, and TLR7 signaling [18]. 
This has been substantiated by an ex  vivo brain tumor 
model, in which mCherry-GL261 glioma cells were inoc-
ulated into brain slices [5, 12, 27]. Using this model, we 
explored whether TLR5 activation plays a role in glioma 
growth in brain slices derived from WT and Tlr5−/− 
mice. Tumor sizes were compared after 4 d post-injec-
tion. No significant differences with respect to tumor 
volume between WT and Tlr5−/− mice were detected 
(Additional file 4a). Likewise, when mCherry-GL261 gli-
oma cells injected into WT brain slices were exposed to 
flagellin for 4 d, no significant impact on glioma growth 
was observed (Additional file 4b).
Microglia exposed to flagellin contribute to neuronal 
apoptosis through TLR5
Microglia can trigger neurodegeneration through TLRs 
including TLR2, TLR3, TLR4, TLR7, and TLR9 [6, 30, 
36, 38, 40]. To test whether activation of TLR5 in micro-
glia affects neuronal survival, co-cultures of neurons 
and microglia derived from WT or Tlr5−/− mice were 
exposed to flagellin. Assessment of the relative neuronal 
viability revealed that flagellin induced neuronal loss 
(Fig.  5a) in a dose (Fig.  5b)- and time (Fig.  5c)-depend-
ent manner. Under control conditions, microglia co-cul-
tured with neurons did not significantly affect neuronal 
(See figure on next page.)
Fig. 3 Flagellin triggers chemotaxis, but not random motility in microglia, through TLR5 and PI3K/PDK1/Akt/mTORC1 signaling. a–c Microglial 
migration in response to flagellin (FLA) was analyzed by agarose spot assay. a Images of FLA- and PBS (control)-treated C57BL/6 microglia. Scale 
bar, 100 μm. b Various FLA doses, as indicated, were added either to the spot alone (gradient/black, n = 8) or c to both the spot and the culture 
medium (no gradient/grey, n = 4). PBS was used as negative control. Microglial migration was quantified after 6 h of FLA incubation. Results are 
expressed as mean ± SEM. Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. *P < 0.05; **P < 0.01 vs. control; ##P < 0.01. d 
Microglial migration in response to FLA was analyzed by Boyden chamber assay. Images of C57BL/6 microglia plated in the upper compartment 
and treated with 100 ng/ml FLA. PBS served as control. Scale bar, 100 μm (upper panel). Microglial migration in response to various FLA doses, as 
indicated, was quantified after 6 h (lower panel, n = 10). Results are expressed as mean ± SEM. Data were analyzed by one-way ANOVA followed 
by Dunnett’s post hoc test. **P < 0.01 vs. control. e Quantification of microglia plated in both wells of the Boyden chamber lacking a gradient 
(n = 10). Results are expressed as mean ± SEM. Data were analyzed by one-way ANOVA followed by Dunnett’s post hoc test. n.s., not significant. 
f Agarose spot assay testing microglial migration, as described in (a, b) in the presence of various doses of mouse TLR5-neutralizing antibody 
(anti-mTLR5), as indicated (n = 4). Results are expressed as mean ± SEM. Data were analyzed by one-way ANOVA followed by Dunnett’s post hoc 
test. **P < 0.01 vs. control; ##P < 0.01. g Agarose spot assay testing microglial migration, as described in (a, b) in the presence of LY294002 (25 and 
50 μM) and Wortmannin (0.1 and 1 μM), n = 12. Results are expressed as mean ± SEM. Data were analyzed by one-way ANOVA followed by Tukey’s 
post hoc test. **P < 0.01 vs. control; ##P < 0.01 vs. FLA. h FLA-induced (100 ng/ml) microglial migration in the Boyden chamber in the presence of 
LY294002 (25 and 50 μM), Wortmannin (0.1 and 1 μM), rapamycin (10 and 100 μM), or anti-mTLR5-IgG (1 μg/ml), n = 12. Results are expressed as 
mean ± SEM. Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. **P < 0.01 vs. control; ##P < 0.01 vs. FLA. (i) FLA-induced 
(100 ng/ml) microglial migration tested by agarose spot assay in the presence of rapamycin (10 and 100 μM) or Akt inhibitor IV (1 μM), n = 4. Results 
are expressed as mean ± SEM. Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. **P < 0.01 vs. control; ##P < 0.01 vs. FLA. g–i 
DMSO-containing DMEM served as control, while FLA was solved in DMSO-containing DMEM
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survival, and 1 ng/ml flagellin also had no significant toxic 
effect within 72  h (loss of NeuN-positive cells by 4.1% 
(± 1.8, P = 0.1443)). In contrast, 10 ng/ml and 100 ng/ml 
flagellin induced neuronal loss by 19.2% (± 3.4, P = 0.017) 
and 30.9% (± 4.1, P = 0.0042), respectively, compared 
to control condition after 72  h (Fig.  5b). While expo-
sure to 100  ng/ml flagellin did not significantly reduce 
neuronal viability within 12  h (15.2% ± 2.3, P = 0.2177; 
data not shown), neuronal loss was observed after 1 
d, 3 d, and 5 d of flagellin treatment by 26.8% (± 12.0, 
P = 0.0363), 30.9% (± 4.1, P = 0.0153), and 32.0% (± 7.9, 
P = 0.0211), compared to control, respectively (Fig.  5c). 
In accordance with this, flagellin treatment caused an 
increase in TUNEL-positive cells in neuronal cultures 
in the presence of WT microglia (Fig.  5d, e). Flagellin-
induced neurotoxicity required microglial TLR5, as neu-
rons co-cultured with Tlr5−/− microglia were protected 
from flagellin-induced neurotoxicity (Fig.  5a–c). To test 
whether this neurotoxicity requires microglia, we incu-
bated purified cortical neurons with flagellin, LPS, which 
induces neuronal injury through microglial TLR4 in co-
cultures [40], or loxoribine, an established TLR7 ligand 
known to induce cell-autonomous neuronal apopto-
sis [36]. Assessment of the relative neuronal viability 
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revealed that cortical neurons were not affected by flagel-
lin in the absence of microglia during the whole observa-
tion period (Fig. 5f, g). Likewise, in contrast to loxoribine, 
LPS did not affect neuronal survival in cultures of puri-
fied neurons, as expected (Fig. 5f ).
In summary, these findings demonstrate that activation 
of TLR5 in microglia results in neuronal apoptosis.
Intrathecal flagellin induces neuronal injury in the cerebral 
cortex
To evaluate the functional role of flagellin as TLR5 
activator in the CNS in  vivo, we injected mice 
intrathecally with flagellin or PBS serving as control. 
Immunohistochemical analysis of the cerebral cor-
tex 72 h after injection revealed that flagellin induced 
significant neuronal loss of 32.3% compared to con-
trol as revealed by combined NeuN and DAPI labe-
ling (Fig. 6a, b). Induction of apoptosis in the cerebral 
cortex was confirmed by immunostaining of active 
caspase 3-positive cells, which were increased by 
58.0% in flagellin-injected animals compared to con-
trol (Fig.  6c). Furthermore, intrathecal application of 
flagellin led to increased microglial numbers (52.3%) 
in the cerebral cortex compared to control condition 
(Fig. 6d, e).
Fig. 4 Flagellin-induced microglial phagocytosis is mediated by TLR5 and the PI3K/PDK1/Akt/mTOR pathway. a Using FACS-based phagocytosis 
assay incorporation of Alexa Fluor 405-labelled beads into microglia was quantified. The image shows representative histograms, in which peaks 
represent the number of microglia that phagocytosed none or one to four beads in the absence (control, black) and presence of flagellin (FLA, 
100 ng/ml, gray). b The phagocytic index derived from the data shown in (a) was determined and normalized to control. In addition, FLA-treated 
microglia in the presence of LY294002 (50 μM), Wortmannin (1 μM), rapamycin (100 μM), or anti-mTLR5-IgG (1 μg/ml) were tested (n = 4). 
DMSO-containing DMEM served as control, while FLA was solved in DMSO-containing DMEM. Results are expressed as mean ± SEM. Data were 
analyzed by one-way ANOVA followed by Tukey’s post hoc test. **P < 0.01 vs. control; ##P < 0.01 vs. FLA
(See figure on next page.)
Fig. 5 Flagellin induces neuronal cell death through TLR5 in vitro. a Co-cultures of C57BL/6 (WT) neurons and WT or Tlr5−/− microglia were 
incubated with 100 ng/ml flagellin (FLA) for 72 h. Subsequently, cells were stained with NeuN antibody to mark neurons, and DAPI to label nuclei, 
and representative images are shown (scale bar, 50 μm; n = 3). b, c NeuN-positive cells in co-cultures treated with different FLA doses, as indicated, 
for 72 h (b), or with 100 ng/ml FLA for different time periods, as indicated (c), were quantified, and results were expressed as relative neuronal 
viability by setting the viability of control cells to 100%. 1 μg/ml LPS served as positive control, whereas unstimulated condition served as negative 
control (n = 3). d Images of TUNEL-positive and DAPI-labeled nuclei in unstimulated (control) and FLA-treated co-cultures containing WT microglia 
are shown (scale bar, 50 μm; n = 4). e Quantification of TUNEL-positive cells in co-cultures incubated with different FLA doses, as indicated, and with 
LPS, serving as positive control, relative to control (n = 4). Data are expressed as mean ± SEM. Results were analyzed by Kruskal–Wallis test followed 
by Dunn’s post hoc test. *P < 0.05; **P < 0.01 vs. control; #P < 0.01 vs. Tlr5−/−. f, g Purified neurons from C57BL/6 mice were incubated with various 
FLA doses, as indicated, 1 μg/ml LPS, or 1 mM loxoribine (LOX) for 72 h (f), or were incubated with 100 ng/ml FLA for indicated durations (g, n = 3). 
Subsequently, cells were stained with NeuN antibody and DAPI. NeuN-positive cells were quantified, and results were expressed as relative neuronal 
viability by setting the viability of control cells to 100%. Data are expressed as mean ± SEM. Results were analyzed by Kruskal–Wallis test followed by 
Dunn’s post hoc test. *P < 0.05 vs. control; n.s., not significant
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Taken together, the TLR5 activator flagellin induces 
neuronal injury in the cerebral cortex in vivo.
Discussion
Microglia express all TLRs identified so far, and TLR 
signaling can have a profound impact on microglial func-
tion. TLR4 activation by its established ligand LPS, for 
example, triggers cytokine release from microglia and 
affects their proliferation [40, 60, 65]. TLR1/2 signal-
ing in microglia promotes a pro-tumorigenic phenotype 
of these cells [18], whereas TLR2 and TLR7 modulate 
microglial chemotaxis and cytokine release [29]. More-
over, activation of microglial TLR2, TLR4, and TLR7 
contribute to neuronal injury [40, 41]. Although TLR5 
expression in human and mouse microglia was pre-
viously described [4, 52], and a few studies recently 
Fig. 6 Intrathecal flagellin triggers neuronal injury in the cerebral cortex. 1 μg of flagellin (FLA) was injected intrathecally into C57BL/6 mice (n = 4), 
while PBS served as control (n = 4). a After 3 d, brain sections were stained with NeuN antibody and DAPI, and representative images are shown 
(scale bar, 50 μm). b The density of NeuN-positive cells in the cerebral cortex was assessed. c Sections were stained with active caspase-3 antibody 
(images are not shown), and caspase-3-positive cells in the cerebral cortex were quantified. d Sections were immunostained with Iba1 antibody 
and DAPI, and e Iba1-positive cells in the cerebral cortex were quantified. Results are presented as mean ± SEM. Data were analyzed by Student’s 
t-test and provided indicated P values
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reported on a functional relevance for this receptor in the 
setting of various CNS disorders including neuropathic 
pain, stroke, and Alzheimer’s disease (AD) [7, 24, 33, 64], 
its mode of action and functional consequences of this 
receptor activation in the brain has not been explored. 
While for most of the TLRs several agonists derived 
from pathogens and host-derived tissue were identified 
[61], the bacterial protein flagellin is the only established 
natural ligand for TLR5. Yet conversely, flagellin seems 
to activate further receptor systems, as flagellin from 
Legionella pneumophila triggers the release of proinflam-
matory molecules such as IL-1β from microglia, through 
the inflammasome Naip5-NLRC4 complex [32]. How-
ever, flagellin from Salmonella typhimurium as used in 
our current study did not result in IL-1β secretion from 
microglia, suggesting a pathogen-specific activation of 
TLR5 and subsequent phenotype induction in these cells.
TLR signaling plays a major role in initiating host 
defense responses in CNS microbial infection. While 
several TLRs including TLR4, which recognizes Gram-
negative bacteria, TLR2, which detects lipoproteins 
from Gram-positive bacteria, and TLR9 as a sensor for 
bacterial and viral DNA, were extensively studied in 
CNS infection [20], data on TLR5 function in this con-
text are rare. Among other TLRs, TLR5 in primate 
microglia, and also astrocytes, triggers the production 
of proinflammatory molecules in response to Borrelia 
burgdorferi, thereby possibly contributing to Lyme neu-
roborreliosis [3]. Furthermore, TLR5 senses flagellin 
from Listeria monocytogenes [22], which represents one 
of the major pathogens causing bacterial meningitis in 
humans. In our study, we demonstrate that exposure to 
flagellin modulates diverse functions of mouse micro-
glia as the brain’s primary immune cells. First, it triggers 
the release of specific inflammatory molecules, second, 
it modulates chemotaxis, third, it increases phagocy-
tosis, and finally, it triggers neuronal apoptosis through 
microglial activation. All these effects require functional 
TLR5 signaling, as demonstrated in experiments using 
Tlr5−/− microglia and/or TLR5-neutralizing antibody. 
Moreover, our study provides evidence that activation of 
TLR5 in microglia triggers the PI3K/Akt/mTORC1 path-
way, which is required for the different microglial func-
tions described above. Our findings in microglia are in 
line with studies on peripheral macrophages, in which 
flagellin triggers the release of TNF-α through PI3K/Akt/
mTORC1 signaling [2]. However, the downstream sign-
aling cascade induced by activation of distinct TLRs in 
microglia seems to involve different molecular compo-
nents, as PI3K and Rac inhibition impairs both TLR2- 
and TLR7-mediated microglial migration, whereas Akt 
phosphorylation is required only for TLR2-, but not for 
TLR7-induced migration [29]. In peripheral immune 
cells, the intracellular TLR adapter MyD88 represents a 
common link for TLR2, TLR5, and TLR7 signaling [35]. 
Although not investigated in our study, this adapter is 
likely required in microglial TLR5 signaling as well, as 
it is crucial for microglial TLR2 and TLR7 signaling 
[36, 41]. Interestingly, the release of MIP-2 from micro-
glia exposed to LPS was significantly enhanced in the 
absence of TLR5, while IL-6 and IL-10 responses were 
reduced compared to wild-type cells. One may specu-
late that TLR5 cooperates with TLR4 [28], which is 
the LPS-recognizing receptor, in an unknown manner, 
resulting in enhancing (IL-6, IL-10) or inhibiting (MIP-2) 
effects on cytokine production. In addition, as TLR5 can 
interact with TIR-domain-containing adapter-inducing 
interferon-β (TRIF), LPS stimulation might modulate 
the cytokine response through the associated pathway 
[8]. Furthermore, while microglial production of the par-
ticular cytokines/chemokines in response to flagellin was 
clearly mediated by TLR5 in our study, other receptors 
and downstream signaling pathways activated by flagel-
lin, which trigger different cytokine responses and sub-
sequently induce a specific microglial phenotype may 
exist. The observed reduction in the microglial release of 
cytokines at higher flagellin doses may be explained by 
the fact that the interaction between TLR5 and flagellin 
is based on protein structure-mediated receptor-ligand 
binding at the ratio of 1:1. In addition, flagellin is capable 
of interacting with itself through the backbone protein 
[66]. Thus, at 100 ng/ml flagellin saturation of the recep-
tor system in microglia might be achieved, and higher 
flagellin doses (1000  ng/ml) may form flagellin aggre-
gates, which inhibit further linear activation. Finally, 
TLR5-mediated signaling in microglia may be negatively 
regulated at specific flagellin concentrations. In general, 
protein interactions within the TLR signaling pathway 
are targeted by one specific or several inhibitors [16], 
and fine-tuning of the TLR5 signaling pathway might be 
achieved not only through a cascade of regulators, but 
also by specific ligand concentrations.
Microglia are activated in essentially all CNS disor-
ders, and the subsequent neuroinflammation, in its char-
acteristic form common to various neurodegenerative 
diseases, is shaped by their migratory, phagocytic, and 
antigen-presenting properties. As discussed above, TLRs 
detect pathogen-associated components, but can also 
be activated by host-derived factors. For instance, the 
extracellular matrix component versican activates TLR2, 
tenascin C and heat-shock protein 60 signal through 
TLR4, and sequence-specific microRNAs activate TLR7 
[5, 17, 27, 36, 41]. Recognition of such endogenous mol-
ecules, potentially derived from injured host tissue, 
by TLRs and the subsequent inflammatory response 
may have important pathological implications, as both 
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processes contribute to various CNS injury models, 
including mouse models for various neurodegenerative 
diseases [41, 53]. Notably, TLR5 specifically recognizes 
flagellin from bacteria, and bacterial infection has been 
associated with the increased occurrence of neurode-
generative diseases, such as AD [26, 44, 49]. While in 
the healthy state, TLR5 expression in mouse and human 
brain is only weak [21, 42], expression of TLR5 mRNA 
in the AD cortex is increased and correlates with the 
expression of the constitutive microglial cell marker 
Iba1 [7, 24]. Matching our findings in mouse microglia, 
human THP-1 monocytes exposed to flagellin release 
cytokines including TNF-α, and this release is prevented 
by TLR5 inhibition [24]. Consistent reports of increased 
TLR5 expression exist in the context of further neuro-
degenerative disorders, such as Parkinson’s disease and 
dementia with Lewy bodies [14, 43]. We report herein 
that TLR5 is abundantly expressed in adult microglia 
whose activation represents a major hallmark in neuro-
degenerative diseases, and that signaling through this 
receptor contributes to neuronal apoptosis. Taking into 
account that TLR5 activation seems to be involved in the 
different pathological states outlined above, it is conceiv-
able that endogenous, yet unidentified ligands for TLR5 
exist. In accordance with this, contribution of TLR5 to 
further CNS pathologies was recently reported. In neu-
ropathic pain, TLR5 function is involved in mechanical 
allodynia [64], while in stroked mice, TLR5 activation 
induces NF-κB via Akt phosphorylation [33], match-
ing our data on flagellin-increased Akt phosphorylation 
in microglia. Besides injecting mice intrathecally with 
flagellin as a proof-of-concept demonstration for a role 
of activated TLR5 in neuronal injury, we herein tested 
the impact of TLR5 signaling in the setting of glioblas-
toma, the most aggressive brain tumor in adults. The 
experiments using the GL261 glioma mouse model were 
prompted by our previous results on the promotion of 
tumor growth involving TLR2, TLR4, and TLR7 signal-
ing [5, 12, 27], and were driven by the assumption that 
TLR5 might detect host-derived molecules. In line with 
this, high mobility group box 1 was recently suggested to 
bind to TLR5, thereby activating proinflammatory sign-
aling with the functional consequence of pain [10]. In 
our experimental glioma set-up, however, neither TLR5 
stimulation by flagellin nor deletion of TLR5 signaling 
as assessed by analyzing Tlr5−/− mice, had an impact on 
glioma growth. Therefore, TLRs do not seem to be uni-
formly involved in the regulation of glioma growth.
Conclusions
Our study establishes TLR5 and its ligand flagellin as 
modulators of microglial function and neuronal apopto-
sis. Further research will be required to investigate the 
probably more complex role of TLR5 in the CNS and to 
establish clinical consequences of CNS injury triggered 
by this receptor in distinct CNS disorders, such as bac-
terial infection and neurodegenerative diseases. Finally, 
TLR5 signaling and subsequent regulation of microglial 
function may be important not only for pathological but 
also for physiological processes in the CNS.
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